2例脑死亡无偿器官捐献供体的维护体会

目的探讨脑死亡器官移植供体的维护要点。方法我院于2011年12月至2012年1月期间共完成2例脑死亡器官捐献(DBD)供体的无偿器官捐献工作。供体确诊为脑死亡,应用机械通气、血管活性药物及其他相关药物维持供体,监测有创动脉压、中心静脉压、心率、血气交换、尿量、电解质酸碱平衡、体温、血细胞比容、白蛋白水平等,维持供体器官灌注。结果 2例DBD供体维持生命体征平稳,捐献的器官功能稳定正常。其中,供体1在入ICU后6 h确诊脑死亡,到实施器官捐献共维护33 h;供体2在入ICU后8 h确诊脑死亡,到实施器官捐献共维护31 h。捐献的肝脏、肾脏和角膜均成功移植于受体。结论 DBD供体维护是确保潜在供体器官成功捐献和捐献器官移植手术成功的关键因素之一,对有效提高捐献器官的利用率及缓解目前器官短缺状况起到很重要的作用。     

伴急性肾损伤的脑死亡器官捐献供者供肾移植治疗的体会

目的总结伴急性肾损伤(AKI)的脑死亡器官捐献(DBD)供者供肾移植的治疗效果。方法选取成功完成DBD供肾移植的59例供者纳入本研究,根据入重症监护室(ICU)时的血清肌酐(Scr)水平,将DBD供者分为AKI组(14例)与正常组(45例),相应的101例受者根据供者情况分为AKI组(23例)与正常组(78例)。总结59例供者器官捐献情况,比较两组供者获取前的主要指标。比较两组受者术后肾功能、住院情况及临床结局。结果 59例供者中,14例发生AKI(24%),其中2例在其维护期间行持续性肾脏替代治疗。与正常组供者相比,AKI组供者的急性生理与慢性健康(APACHE)Ⅱ评分明显升高(P0.05),中枢性尿崩症的发生率更高(P0.01),入ICU时和获取前的Scr水平更高(均为P0.01),获取前24 h尿量更少(P0.01)。与正常组受者相比,AKI组受者术后2、3 d的Scr水平更高(均为P0.05),住院时间和住院花费亦明显升高(P0.01,P0.05)。两组受者术后移植肾功能延迟恢复、急性排斥反应、感染、恢复透析的发生率比较,差异无统计学意义(均为P0.05)。术后3个月,两组受者均好转出院,移植肾存活率为100%。结论伴AKI的DBD供者供肾移植,经过积极的器官维护可纠正AKI,达到与非AKI供肾同样的效果,可以作为扩大供肾来源的途径。     

公民逝世后器官捐献供肾移植临床分析

目的探讨公民逝世后器官捐献供肾移植的近期临床效果。方法公民逝世后器官捐献供肾移植73例,供者43例,其中本院器官获取组织42例,外院器官获取组织分享1例。分析肾移植术后人/肾存活率和并发症的发生情况。结果 73例受者随访9~38个月,术后6个月、1年的人/肾存活率分别为97.3%/94.5%、94.5%/91.8%。10例(13.7%)受者发生移植肾功能恢复延迟,15例(20.5%)受者术后发生急性排斥反应,21例(28.8%)受者发生肺部感染。2例受者移植肾丢失,4例受者移植肾带功死亡。结论公民逝世后器官捐献供肾移植近期疗效较好,是解决供肾来源的有效途径。     

DBCD供体状态与器官移植受者术后器官功能恢复的相关性分析

目的探讨脑-心双死亡器官捐献(DBCD)供体状态与其肝、肾移植受者术后器官功能恢复的相关性。方法回顾性分析2011年8月至2013年11月四川省人民医院器官移植中心的12例DBCD供体评估资料及器官保护措施,以及由其提供器官的12例肝移植、22例肾移植受者术后恢复的各项指标。将供体各项指标分别与其肝移植、肾移植受者术后恢复指标进行相关性分析。结果肝移植受者术后发生肝脏原发无功能(PNF)1例(1/12,8%),肾移植受者术后发生移植物功能延迟恢复(DGF)11例(11/22,50%)。经统计学分析,供体入住重症监护室(ICU)时间、肝功能、维持收缩压、凝血功能、血糖、电解质(血Na+、K+)等指标,与其肝、肾移植受者术后器官功能恢复的相关性均有统计学意义(均为P﹤0.05)。年龄、脑死亡原因、维持舒张压、活化部分凝血活酶时间(APTT)、动脉血p H值与其相应肝移植受者术后恢复存在相关性。总胆红素、白细胞计数与其相应肾移植受者术后恢复存在相关性。结论 DBCD供体是适合我国国情的器官移植供体。DBCD肝移植受者术后PNF发生率较低,肾移植受者术后DGF发生率较高。根据影响因素有针对性地进行供体评估和器官保护工作,有助于提高DBCD的肝、肾移植效果。     

甲基苯丙胺中毒脑死亡器官捐献1例报道

目的探讨甲基苯丙胺中毒脑死亡器官捐献供肾肾移植的效果。方法回顾性分析2015年10月1例甲基苯丙胺中毒脑死亡器官捐献供肾用于2例肾移植的临床资料。供者为女性,22岁,因甲基苯丙胺中毒导致脑死亡而捐献器官。受者均为女性,因慢性肾功能不全尿毒症接受肾移植。结果 2例受者术后4 d血清肌酐恢复正常,未发生急性排斥反应。术后1年随访血清肌酐及尿量均正常。结论甲基苯丙胺中毒脑死亡的患者可以作为器官捐献的供体来源。     

移植肾功能恢复延迟高危供者的评估及肾脏修复

我国自2015年1月1日开始,器官捐献成为我国器官移植唯一的合法来源。而公民逝世后器官捐献尸体供肾也带来一些移植术后并发症,特别是移植肾功能恢复延迟(delayed graft function,DGF)的发生率增加。导致公民逝世后器官捐献尸体供肾移植术后DGF的因素主要有:①DCD和ECD供体增多;②供体治疗、维护、获取和术后管理过程中供肾损伤;③传统静态冷保存技术不能满足需求。针对这些问题临床医生要做到以下几点:①对供体要做全面的评估,利用评估标准合理取舍供体,预测DGF风险;②对供体尽心维护,采取有效措施、降低高危因素引起供肾的损害;③对获取的供肾精心修复,采用以低温机械灌注保存为主的有效方法修复器官损害;④加强移植术后受者的管理,预见性防治措施降低DGF发生率。总之,依据临床工作的实际情况,结合器官获取和临床移植工作的操作流程,进行供肾评估与修复具有十分重要的意义。     

心脏死亡供肾肾移植9例临床分析

目的 探讨心脏死亡无偿器官捐献肾脏移植治疗的经验及效果.方法 分析我院于2007年9月至2012年1月完成的9例心脏死亡无偿器官捐献肾移植的临床资料.根据＂脑死亡判定标准（成人）＂和＂脑死亡判定技术规范＂确诊为供体脑死亡,待心脏停止跳动后,按常规方法整块切取器官.其中7例接受4例院内脑死亡后心脏死亡（DCD）患者的无偿供肾,2例患者接受1例院外脑死亡后心脏死亡患者的无偿供肾.结果 所有患者手术顺利.4例受者术后第5天肾功能恢复正常.1例受者术后出现急性排斥反应,给予抗人胸腺细胞免疫球蛋白（ATG）冲击治疗并辅以血液透析.4例术后肾功能延迟恢复.所有受者随访3个月~5年.2例术后死于重症感染及进行性多灶性白质脑病,死亡时肌酐431.6μmol/L和105.3 μmol/L.结论 心脏死亡器官捐献是扩大器官来源的有效途径,近期移植效果可靠可以用于临床.     

儿童器官捐献供体肝肾联合获取经验总结

目的探讨儿童器官捐献供体肝肾联合获取的临床经验。方法收集2011年10月至2016年12月佛山市第一人民医院6例儿童器官捐献供体肝肾联合获取的临床资料,总结其临床经验。结果根据国家卫生和计划生育委员会脑损伤质控评价中心制定的儿童脑死亡判定标准,6例儿童供体均在脑死亡状态下进行器官捐献肝肾联合获取,采用7号吸痰管髂外动脉插管或24 F导尿管髂总动脉插管、门静脉和腹主动脉灌注、胸主动脉阻断的肝肾联合灌注的改良方法。手术时间55~60 min,共成功获取6个供肝、12个供肾,所获取肝肾均成功应用于临床肝、肾移植,受者均未发生移植肝或移植肾原发性无功能。结论在儿童器官捐献供体中成功进行肝肾联合获取的关键在于及时进行脑死亡判定、严格谨慎的器官维护措施和肝肾联合获取技术的改良。     

儿童器官捐献供肾肾移植疗效的临床研究

目的探讨儿童器官捐献供肾移植的近期临床疗效。方法回顾性分析2013年11月至2015年12月西安交通大学第一附属医院肾移植科完成的15例儿童器官捐献供者,供给28例肾移植受者(其中双肾移植2例)的供、受者临床资料。结果 28例受者手术均获成功。移植肾热缺血时间中位数为12.5 min(0~17.0 min),冷缺血时间中位数为4.3 h(1.5~7.7 h)。术后出现移植物功能延迟恢复(DGF)4例、透析1例、因肺部感染死亡2例、肾吻合口狭窄和供肾血栓形成后切除移植肾各1例。术后随访1~24个月,受者存活26例(93%),带肾存活受者24例(86%),其移植肾功能均正常。结论儿童器官捐献供者双肾整块移植及单肾移植早期临床疗效较好。     

脑死亡器官捐献单中心经验（附26例报告）

目的总结脑死亡器官捐献单中心经验。方法回顾性分析2006年3月至2012年6月解放军第181中心医院全军肾移植与透析治疗中心完成的脑死亡器官捐献与移植案例。结果共完成脑死亡器官捐献26例,进而完成52例肾移植和8例肝移植,移植器官功能均良好。其中48例肾移植受者总存活率92．2％,移植肾总存活率83．7％。结论脑死亡器官捐献是器官移植重要的器官来源,但在我国尚处于起步阶段,进一步发展需取决于相关法律法规的制定以及捐献者、受者、医疗机构的权责是否得到明确和保证。     

Donors With Immune Thrombocytopenia: Do They Pose a Risk to Transplant Recipients?

Transplant‐mediated alloimmune thrombocytopenia (TMAT) from donors with immune thrombocytopenia (ITP) can result in significant bleeding complications in the recipient. The risk to a recipient of TMAT if they receive an organ from a donor with ITP is unknown. The outcomes of recipients of organs from deceased donors with ITP recorded in the UK Transplant Registry between 2000 and 2015 were reviewed. Twenty‐one deceased organ donors had a predonation diagnosis of ITP. These donors were significantly more likely to have died from intracranial hemorrhage than were all other deceased organ donors (85% vs. 57%, p < 0.001). Organs from donors with ITP resulted in 49 organ transplants (31 kidney, 14 liver, four heart), with only one case of TMAT, which occurred in a liver transplant recipient and resulted in death from bleeding complications 18 days posttransplantation. The recipient of a kidney from the same organ donor was not affected. Unadjusted 5‐year patient and graft survival was significantly worse for liver transplant recipients from donors with ITP compared with liver transplant recipients from donors without ITP (64% vs. 85%, p = 0.012). Organs from donors with ITP may be considered for transplantation, but livers should be used with caution.     

Clinical analysis on 48 cases of kidney transplantation from brain and cardiac death donors

Objective To observe the short-term clinical outcomes of kidney transplantation from brain and cardiac death donors (DBCD) and assess its feasibility to expand organ donor pool. Methods A retrospective analysis was performed on 48 cases of kidney transplantation from DBCD.The transplant recipients had finished 12-month follow-up in the First People's Hospital of Foshan from September 2011 to February 2015, with their renal function, rejection reaction and complications at 1 week, 1 month, 3 months, 6 months and 12 months after renal transplantation being collected. Survival rates of transplant recipients and transplant kidneys, incidence of delayed graft function (DGF) and its influence for recipients and graft survival were analyzed by statistics. Results In the 48 cases, the survival rates of recipients at 1, 3, 6 and 12 months after transplantation were 100.0%, 100.0%, 97.9%, 95.8%, and the survival rates of transplanted kidneys were 95.8%, 95.8%, 93.8%, 91.7%, respectively. DGF occurred in 8 of 48 (17.0%), but the occurrence of DGF did not adversely influence patient's survival (P=0.524) or graft survival (P=0.362). Conclusions The short-term clinical outcomes of kidney transplantation from DBCD are ideal. As the legislation of donation after brain death (DBD) has not been ratified in China, the kidney transplantation from DBCD could be an important way to solve the shortage of organs, and increase the number of kidneys available for transplantation.     

357例儿童死亡后器官捐献供肾移植血栓性并发症回顾性分析

目的回顾性分析本中心儿童死亡后器官捐献(deceased donor,DD)供肾移植血栓性并发症的发生率以及相关影响因素。方法收集中南大学湘雅二医院2012年1月—2018年12月完成的357例儿童DD供肾移植相关资料,将其分为三组,将297例单肾移植设为组一,60例双肾移植中,32例供体满足三“5”原则(供体年龄>5个月,供体体重>5 kg,供肾长径>5 cm)设为组二,28例不满足三“5”原则者设为组三,统计血栓性并发症的发生率,分析供体年龄、供肾大小以及手术方式的选择与术后血栓性并发症的关系。结果组一297例单肾移植受体有2例发生移植肾栓塞,发生率为0.67%,经分析为外科操作失误所致;组二32例双肾移植受体未出现血栓并发症,1例出现肾动脉狭窄;组三中有5例受体发生移植肾栓塞,其中3例单肾动脉栓塞,1例双肾动脉栓塞,1例单肾静脉栓塞,其均为采用分离式双肾移植术式的受体,栓塞发生率为17.8%,而接受“利用主动脉远端建立流出道的双肾移植”术式的18例受体无1例发生栓塞。结论儿童供肾移植术后血栓并发症与供体年龄,供肾大小及外科技术有关。供体年龄<5个月,供体体重<5 kg,供肾长径<5 cm的供体栓塞发生率明显升高。“利用主动脉远端建立流出道的双肾整块移植”术后栓塞发生率低,可有效解决婴幼儿供肾移植栓塞难题,但仍需扩大样本量以及长期随访。     

Transplanting Kidneys from Deceased Donors With Severe Acute Kidney Injury

Our aim was to determine outcomes with transplanting kidneys from deceased donors with acute kidney injury, defined as a donor with terminal serum creatinine ≥2.0 mg/dL, or a donor requiring acute renal replacement therapy. We included all patients who received deceased donor kidney transplant from June 2004 to October 2013. There were 162 AKI donor transplant recipients (21% of deceased donor transplants): 139 in the standard criteria donor (SCD) and 23 in the expanded criteria donor (ECD) cohort. 71% of the AKI donors had stage 3 (severe AKI), based on acute kidney injury network (AKIN) staging. Protocol biopsies were done at 1, 4, and 12 months posttransplant. One and four month formalin‐fixed paraffin embedded (FFPE) biopsies from 48 patients (24 AKI donors, 24 non‐AKI) underwent global gene expression profiling using DNA microarrays (96 arrays). DGF was more common in the AKI group but eGFR, graft survival at 1 year and proportion with IF/TA>2 at 1 year were similar for the two groups. At 1 month, there were 898 differentially expressed genes in the AKI group (p‐value <0.005; FDR <10%), but by 4 months there were no differences. Transplanting selected kidneys from deceased donors with AKI is safe and has excellent outcomes.     

Acute kidney injury in donors of donation after brain plus cardiac death does not affect recipients' short-term prognosis in transplantation

Objective To investigate the clinical efficacy of renal transplantation from donors of donation after brain and cardiac death(DBCD) complicated with acute kidney injury (AKI), and summarize the clinical experience of evaluation and application. Methods The clinical data of the 45 DBCD donors and 80 recipients in the First People's Hospital of Foshan from September 2011 to September 2015 were retrospectively analyzed. DBCD donors were classified into the AKI group (n=26)and non-AKI group (n=19) according to the serum creatinine level and urine output when the donors were admitted to the intensive care unit (ICU) in this hospital. A total of 80 recipients were divided into the AKI group (n=46) and non-AKI group (n=34) correspondingly. The condition of the donors before organ procurement between the two groups was compared, and the incidence of various complications, the 1 years survival rates of recipients and graft after renal transplantation were compared between the two groups. Results Among 45 donors, 26 cases(57.8%) suffered from AKI. The serum creatinine of donors was significantly higher in the AKI group than that in the non-AKI group (P＜0.01). The incidence of delayed graft function (DGF) in AKI group and non-AKI group was 21.7% and 8.8% respectively (P＞0.05). After 1 years, the serum creatinine of the recipients in AKI group was significantly higher than that in non-AKI group [(134.9±63.4) μmol/L vs (106.6±28.2) μmol/L, P＜0.05], but the survival rates of recipients and grafts did no differ between the two groups (both P＞0.05). Conclusions The donors combined with AKI do not have a worse effect on the incidence of DGF, the 1-year survival rates of recipients and grafts after transplantation. So, the donors with AKI for transplantation can widen the origin of kidney grafts.     

儿童心脏死亡器官捐献供者双肾整块移植早期临床疗效观察

目的：观察儿童心脏死亡器官捐献（ DCD ）供者双肾整块移植的早期临床疗效。方法回顾性分析中山大学附属第一医院器官移植中心2010年2月至2013年9月儿童DCD供者双肾整块移植供、受者临床资料。6例儿童DCD供者中位年龄3岁（10个月～6岁）,均捐献给相同血型受者。6例受者中位年龄39．5岁（17～48岁）,成年人5例,17岁男性1例,原发病均为慢性肾小球肾炎;均为首次肾移植,群体反应性抗体均阴性, HLA错配数1～4个。均采用右侧髂窝整块移植法。结果6例受者手术均获成功。移植肾热缺血时间中位数为17．5 min （0～23 min）,冷缺血时间中位数为6．6 h （4．8～7．4 h）。术后肾功能恢复均较顺利,未发生急性排斥反应、移植肾原发性无功能和移植肾功能延迟。其中4例为移植肾功能立即恢复（即术后第5天血清肌酐≤265μmol/L ）,2例为移植肾功能缓慢恢复（即术后第5天血清肌酐＞265μmol/L）。1例受者术后7 d右侧移植肾动脉血栓形成;1例受者术后15 d诊断为肺结核行正规抗结核治疗;1例受者术后1年出现移植肾动脉吻合口狭窄,介入治疗后恢复。术后随访1～36个月,受者和移植肾全部存活,所有受者肾功能均正常。结论儿童DCD供者双肾整块移植早期临床疗效良好,是一种扩大供者来源的良好途径。     

Should hepatitits-C virus antibody-positive donors be excluded from kidney donation?

In organ transplantation, virus transmitted by the donor is associated with a higher risk of severe primary infection after transplantation in the seronegative recipient. In this study, the risk of hepatitis-C virus (HCV) transmission by the kidney was determined, and the morbidity in the recipient assessed. Serum samples from all kidney donors of our Transplantation Unit between 1983 and 1988 were screened for antibodies to anti-HCV by first enzyme-linked immunosorbent assay (Ortho ELISA) and positive samples were confirmed by a second-generation ELISA and the CHIRON RIBA HCV test. Of the 164 kidney donors whose sera were available, five were positive (3%) and all of them were positive with the RIBA test. Liver function was normal in the five donors. Seven recipients received a renal transplant from the anti-HCV-positive donors. Two patients had a follow-up too short to draw any conclusions. Two patients remained anti-HCV-negative up to 36 and 48 months, respectively, but one of them had chronic hepatitis. One patient was anti-HCV-positive before transplantation and remained positive over the 4-year follow-up. The two last patients seroconverted and acute hepatitis occurred at 16 and 101 days after transplantation, respectively. In both cases, no peroperative or postoperative transfusion was given and no other cause of hepatitis could be determined. A cirrhotic evolution was observed within 15 and 36 months in both cases. Thus HCV can be transmitted by a kidney transplant and cadaveric donors positive for anti-HCV antibodies should be excluded from kidney donation.     

Infection with human immunodeficiency virus in the Pittsburgh transplant population. A study of 583 donors and 1043 recipients, 1981-1986

We performed a retrospective serologic survey of 583 organ donors and 1043 transplant recipients for antibodies to human immunodeficiency virus type 1 (HIV-1). Two (0.34%) of the 583 donors and 18 (1.7%) of the 1043 recipients had HIV-1 antibodies by enzyme immunoassay and by Western blot. Two of 5 seropositive recipients tested also had blood cultures positive for HIV-1. Seven (0.7%) of the 1043 transplant recipients had antibodies to HIV-1 before transplantation; 2 of these had hemophilia A, and 5 had previous transfusions. Eleven (1.3%) of 860 recipients followed for 45 days or more seroconverted to HIV-1 a mean of 96 days after transplantation. Likely sources of HIV-1 infection for 3 of these 11 recipients included a seropositive organ donor in 1 patient and high-risk blood donors in 2 patients. A definite source of HIV-1 infection was not found for the other 8 recipients, 3 of whom seroconverted to HIV-1 after institution of blood donor screening for HIV-1 antibodies. Seroconversion to HIV-1 was less common in kidney recipients than in liver, heart, or multiple-organ recipients (P less than 0.02). Nine (50%) of the 18 HIV-1 seropositive transplant recipients died a mean of 6 months after transplant surgery, and 9 (50%) are still alive a mean of 43 months after transplantation. AIDS-like illnesses occurred in 3 of the dead and 1 of the living patients and included pneumocystis pneumonia (3 cases), miliary tuberculosis (1 case), and recurrent cytomegalovirus infection (1 case). These data suggest that the course of HIV-1 infection is not more severe in transplant recipients receiving cyclosporine than in other hosts and that, despite screening of blood and organ donors, a small number of transplant recipients will become infected with HIV-1.     

Intermediate outcomes of dual renal allografts: the University of Washington experience

PURPOSE: The increased survival advantage of renal transplantation with end stage renal disease combined with an increasing incidence of renal disease fuel an increasing disparity between supply and demand for transplantable kidneys. Despite efforts to increase cadaveric organ donation through education and publicity, the number of cadaveric kidneys transplanted has not increased and in the last year was surpassed by kidneys transplanted from living donors. In an effort to maximize cadaver organ donors use of kidneys from expanded criteria donors has been investigated. In select cases both donor kidneys have been transplanted into a single recipient, which is called dual renal transplant. We report on the 4-year dual renal transplant graft and patient outcomes and compare these to age matched single cadaver kidney transplants. MATERIALS AND METHODS: A retrospective review of 10 dual renal transplant recipients and 10 age matched single cadaver kidney recipients was performed. All patients underwent transplantation at our university between January 1996 and February 1998. Mean followup was 4.1 years (range 2.5 to 5.1) for the dual kidney recipients and 3.6 (0.0 to 5.5) years for the control group. RESULTS: Of the 10 dual renal transplant recipients 7 remain alive and 3 died of nontransplant related causes. Of the 10 single recipients 8 are alive, 1 died of postoperative complications and 1 died of nontransplant related causes. When censored for death with a functioning graft, 7 of 10 dual grafts are functioning at followup with a mean creatinine clearance of 39.4 ml. per minute (range 16.1 to 65.9) and mean serum creatinine of 2.0 mg./dl. (1.1 to 3.9). If not censored for death with a functioning graft, 50% of dual grafts are functioning. Of the 3 graft losses 2 were due to recurrent disease and 1 was attributed to chronic rejection. In the control group 8 of 10 grafts are functioning at current followup (regardless of censoring for death with a functioning graft) with a mean creatinine clearance of 48.7 ml. per minute (range 23.4 to 66.5) and mean serum creatinine of 1.6 mg./dl. (1.2 to 2.4). Of the 2 graft losses 1 resulted from postoperative complications and 1 was due to chronic rejection. CONCLUSIONS At the 4-year followup patients undergoing dual renal transplant have comparable graft function, incidence of graft loss and survival compared to the control group. However, because of our small sample size, differences in the 2 groups may be significant in a larger study. Additional studies need to be conducted to determine if this practice represents an acceptable use of kidneys from expanded criteria donors.     

低龄婴儿双供肾移植给成人22例报道

目的总结单中心低龄婴儿双供肾移植给成人的临床效果。方法回顾性纳入2013年7月至2017年10月华中科技大学同济医学院附属同济医院实施的所有儿童双供肾移植给成人受者共22例临床资料和随访数据。22例供者年龄(2.9±1.7)个月,体重(4.9±1.4)kg,其中15例小于3月龄。受者多为低体重女性成人,体重(46.3±5.6)kg。总结早期移植失败及随访期间移植肾失功或受者死亡原因。根据是否发生单侧移植肾血栓,移植肾功能恢复者又进一步分为双肾存活组和单肾存活组,比较移植肾中-长期功能。结果4例受者在术后早期出现移植失败,包括双肾血栓2例、移植肾破裂切除1例和受者多器官功能衰竭死亡1例。18例受者移植肾功能恢复出院,随访期间因移植肾新生肿瘤切除双肾1例、因复杂全身原因死亡1例、因间质性肺炎死亡1例,余15例受者双肾均存活者10例(中位随访59个月),单肾存活者5例(中位随访48个月)。移植1年时双肾存活组估算肾小球滤过率为(95±27)ml/(min·1.73 m2),显著高于单肾存活组(61±24)ml/(min·1.73 m2)(P<0.05),但3年时分别为(95±21)ml/(min·1.73 m2)和(69±31)ml/(min·1.73 m2),差异缩小,差异无显著统计学意义(P=0.12)。结论低龄婴儿双供肾移植虽然可以扩大供肾来源,但发生早期移植失败和单肾栓塞的风险较高。在单肾存活的情况下,受者仍具有相对满意的中-长期移植效果。